--- title: "Oramed Pharma | 10-K: FY2025 Revenue: USD 2 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/280690051.md" datetime: "2026-03-26T21:18:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280690051.md) - [en](https://longbridge.com/en/news/280690051.md) - [zh-HK](https://longbridge.com/zh-HK/news/280690051.md) --- # Oramed Pharma | 10-K: FY2025 Revenue: USD 2 M Revenue: As of FY2025, the actual value is USD 2 M. EPS: As of FY2025, the actual value is USD 1.5, beating the estimate of USD 1.29. EBIT: As of FY2025, the actual value is USD -15.09 M. Oramed Pharmaceuticals Inc. (Oramed 制药) operates as a single reportable segment focused on research and development activities related to its proprietary products and technologies. #### Segment Revenue - **Revenues**: Oramed 制药 recognized $2,000 thousand in revenue related to the HTIT License Agreement for the year ended December 31, 2025, compared to $0 for the year ended December 31, 2024. #### Operational Metrics - **Cost of Revenues**: The cost of revenues was - $1,987 thousand for the year ended December 31, 2025, primarily due to a payment to the Israel Innovation Authority (IIA) for transferring technology to OraTech, with no costs of revenue for the year ended December 31, 2024. - **Gross Profit**: Gross profit was $13 thousand for the year ended December 31, 2025, compared to $0 for the year ended December 31, 2024. - **Research and Development Expenses**: These expenses were - $6,381 thousand for the year ended December 31, 2025, a decrease of 1% from - $6,324 thousand for the year ended December 31, 2024. - **General and Administrative Expenses**: These expenses increased by 35% to - $8,720 thousand for the year ended December 31, 2025, from - $6,457 thousand for the year ended December 31, 2024. - **Operating Loss**: Oramed 制药 reported an operating loss of - $15,088 thousand for the year ended December 31, 2025, compared to - $12,781 thousand for the year ended December 31, 2024. - **Other Income, Net**: Other income, net was $958 thousand for the year ended December 31, 2025, compared to $0 for the year ended December 31, 2024. - **Interest Expenses**: Interest expenses were $0 for the year ended December 31, 2025, compared to - $853 thousand for the year ended December 31, 2024. - **Financial Income (Loss), Net**: Net financial income was $89,454 thousand for the year ended December 31, 2025, a significant increase from - $2,286 thousand net financial expenses for the year ended December 31, 2024. - **Income (Loss) before Tax Expenses**: Income before tax expenses was $75,324 thousand for the year ended December 31, 2025, compared to a loss of - $15,920 thousand for the year ended December 31, 2024. - **Tax Expenses**: Tax expenses increased to - $11,308 thousand for the year ended December 31, 2025, from - $3,183 thousand for the year ended December 31, 2024. - **Net Income (Loss)**: Oramed 制药 reported a net income of $64,016 thousand for the year ended December 31, 2025, compared to a net loss of - $19,103 thousand for the year ended December 31, 2024. - **Net Income (Loss) Attributable to Company’s Stockholders**: Net income attributable to stockholders was $64,050 thousand for the year ended December 31, 2025, compared to a net loss of - $19,060 thousand for the year ended December 31, 2024. #### Cash Flow - **Cash Flow from Operating Activities**: Used - $9,145 thousand in 2025, compared to - $8,412 thousand used in 2024. - **Cash Flow from Investing Activities**: Provided $5,443 thousand in 2025, compared to $105,817 thousand provided in 2024. - **Cash Flow from Financing Activities**: Used - $4,741 thousand in 2025, compared to - $52,036 thousand used in 2024. #### Unique Metrics / Key Investments - **Cash and Cash Equivalents**: As of December 31, 2025, Oramed 制药 had $45,947 thousand in cash and cash equivalents, and $10,979 thousand in short-term bank deposits. - **Accumulated Loss**: The accumulated loss was - $123,436 thousand as of December 31, 2025. - **Working Capital Surplus**: The working capital surplus decreased to $114,185 thousand as of December 31, 2025, from $137,536 thousand as of December 31, 2024. - **Stock Buyback Program**: During 2025, Oramed 制药 repurchased and retired 899,609 shares of common stock for - $2,155 thousand and an additional 1,155,367 shares for - $2,584 thousand from HTIT. - **Investments at Fair Value**: Totaled $37,595 thousand as of December 31, 2025, for the Tranche A Note, Tranche B Note, and Royalty Purchase Agreement with Scilex. - **Investment in Alpha Tau**: Oramed 制药 acquired approximately 17% of Alpha Tau Medical Ltd. for $36,900 thousand in April 2025, with the fair value of this investment being $71,623 thousand as of December 31, 2025. - **Convertible Secured Promissory Note (Lifeward)**: Oramed 制药 provided Lifeward Ltd. with a $3,000 thousand secured promissory note in November 2025, with a fair value of $4,637 thousand as of December 31, 2025. - **Real Estate Investments**: Oramed 制药 invested in a land parcel for $1,586 thousand in January 2025 and entered into a Profit-Sharing Loan Agreement for a real estate project with a value of $1,890 thousand as of December 31, 2025. #### Outlook / Guidance Oramed Pharmaceuticals Inc. (Oramed 制药) anticipates maintaining current planned activities and expenditures for at least the next 12 months using existing cash resources. Additional financing may be necessary if operating expenses unexpectedly rise. Increased research and development expenses are expected in future periods following the revised oral insulin clinical trial initiation, though these costs will be borne by OraTech. ### Related Stocks - [ORMP.US](https://longbridge.com/en/quote/ORMP.US.md) ## Related News & Research - [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md) - [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md) - [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md) - [Motley Fool names Coca-Cola, P&G, J&J as 20-year dividend kings](https://longbridge.com/en/news/286957643.md) - [Ultragenyx Shareholders Approve Incentive Plan, Elect Directors](https://longbridge.com/en/news/286809118.md)